These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32781390)

  • 1. All-atom simulations to studying metallodrugs/target interactions.
    Janoš P; Spinello A; Magistrato A
    Curr Opin Chem Biol; 2021 Apr; 61():1-8. PubMed ID: 32781390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontiers of metal-coordinating drug design.
    Palermo G; Spinello A; Saha A; Magistrato A
    Expert Opin Drug Discov; 2021 May; 16(5):497-511. PubMed ID: 33874825
    [No Abstract]   [Full Text] [Related]  

  • 3. Metalloproteomics in conjunction with other omics for uncovering the mechanism of action of metallodrugs: Mechanism-driven new therapy development.
    Wang H; Zhou Y; Xu X; Li H; Sun H
    Curr Opin Chem Biol; 2020 Apr; 55():171-179. PubMed ID: 32200302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallodrugs: an approach against invasion and metastasis in cancer treatment.
    González-Ballesteros MM; Mejía C; Ruiz-Azuara L
    FEBS Open Bio; 2022 May; 12(5):880-899. PubMed ID: 35170871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metallodrugs in cancer nanomedicine.
    Peña Q; Wang A; Zaremba O; Shi Y; Scheeren HW; Metselaar JM; Kiessling F; Pallares RM; Wuttke S; Lammers T
    Chem Soc Rev; 2022 Apr; 51(7):2544-2582. PubMed ID: 35262108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR spectroscopy to study the fate of metallodrugs in cells.
    Arnesano F
    Curr Opin Chem Biol; 2021 Apr; 61():214-226. PubMed ID: 33882391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel metals and metal complexes as platforms for cancer therapy.
    Frezza M; Hindo S; Chen D; Davenport A; Schmitt S; Tomco D; Dou QP
    Curr Pharm Des; 2010 Jun; 16(16):1813-25. PubMed ID: 20337575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a Novel Metallomics Tool to Probe the Fate of Metal-Based Anticancer Drugs in Blood Plasma: Potential, Challenges and Prospects.
    Sarpong-Kumankomah S; Gailer J
    Curr Top Med Chem; 2021; 21(1):48-58. PubMed ID: 32600232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.
    Leon IE; Cadavid-Vargas JF; Di Virgilio AL; Etcheverry SB
    Curr Med Chem; 2017; 24(2):112-148. PubMed ID: 27554807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metal/N-heterocyclic carbene complexes: opportunities for the development of anticancer metallodrugs.
    Cisnetti F; Gautier A
    Angew Chem Int Ed Engl; 2013 Nov; 52(46):11976-8. PubMed ID: 24115500
    [No Abstract]   [Full Text] [Related]  

  • 13. NSAID-Based Coordination Compounds for Biomedical Applications: Recent Advances and Developments.
    Santos ACF; Monteiro LPG; Gomes ACC; Martel F; Santos TM; Ferreira BJML
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks.
    Petanidis S; Kioseoglou E; Salifoglou A
    Curr Med Chem; 2019; 26(4):607-623. PubMed ID: 29149832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship.
    Andrés CMC; Pérez de la Lastra JM; Bustamante Munguira E; Andrés Juan C; Pérez-Lebeña E
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria-Targeting Anticancer Metal Complexes.
    Erxleben A
    Curr Med Chem; 2019; 26(4):694-728. PubMed ID: 29521200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs.
    Liu W; Gust R
    Chem Soc Rev; 2013 Jan; 42(2):755-73. PubMed ID: 23147001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
    Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH
    Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speciation of Metal Complexes of Medicinal Interest: Relationship between Solution Equilibria and Pharmaceutical Properties.
    Kiss T; Enyedy ÉA; Jakusch T; Dömötör O
    Curr Med Chem; 2019; 26(4):580-606. PubMed ID: 29521198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of coumarin bearing metal complexes: Where are we headed?
    Balcıoğlu S; Olgun Karataş M; Ateş B; Alıcı B; Özdemir İ
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126805. PubMed ID: 31753700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.